Performance Characteristics of a Calculated Index Control Method for the phi Multianalyte Assay with Algorithmic Analysis.

IF 1.8 Q3 MEDICAL LABORATORY TECHNOLOGY Journal of Applied Laboratory Medicine Pub Date : 2024-11-08 DOI:10.1093/jalm/jfae110
Radwa Ewaisha, Tifani L Flieth, Karl M Ness, Alicia Algeciras-Schimnich, Joshua A Bornhorst
{"title":"Performance Characteristics of a Calculated Index Control Method for the phi Multianalyte Assay with Algorithmic Analysis.","authors":"Radwa Ewaisha, Tifani L Flieth, Karl M Ness, Alicia Algeciras-Schimnich, Joshua A Bornhorst","doi":"10.1093/jalm/jfae110","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Multianalyte assays with algorithmic analysis (MAAAs), such as the Prostate Health Index (phi), are increasingly utilized for generating disease risk scores. Currently, imprecision and bias in phi are not directly monitored by quality control (QC) assessment of the index but rather by QC assessment of individual components. This may not be adequately controlling for imprecision and bias in the calculated multicomponent phi value itself.</p><p><strong>Methods: </strong>Inter- and intra-assay phi precision was compared to precision of the individual component assays. QC measurements from total prostate-specific antigen (PSA), free PSA, and p2PSA were used to calculate a single calculated phi QC metric (PHIc). The frequency of QC failure of PHIc, relative to individual components QC by Westgard rules (13S and 22S), was determined. The effects of varying analyte component assay bias on the resulting PHIc metric were also examined.</p><p><strong>Results: </strong>Average measured phi imprecision (6.7% CV) was higher than individual phi analyte component imprecision (3.9-4.5% CV) across 2 Beckman Coulter Unicel DxI 800 instruments. A retrospective examination of PHIc QC over 84 quality control determinations was concurrently carried out for both PHIc and component assay failure patterns, which were dependent on SDs utilized for Westgard evaluation. Finally, reinforcing nonlinear changes in PHIc were observed in select cases of introduced simulated bias of individual component measurements.</p><p><strong>Conclusions: </strong>An additional calculated phi QC measure can be introduced to monitor MAAA precision/bias, and in principle calculated index controls may represent a complementary supplemental QC method that could be applied to other MAAA indices.</p>","PeriodicalId":46361,"journal":{"name":"Journal of Applied Laboratory Medicine","volume":null,"pages":null},"PeriodicalIF":1.8000,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Applied Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jalm/jfae110","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Multianalyte assays with algorithmic analysis (MAAAs), such as the Prostate Health Index (phi), are increasingly utilized for generating disease risk scores. Currently, imprecision and bias in phi are not directly monitored by quality control (QC) assessment of the index but rather by QC assessment of individual components. This may not be adequately controlling for imprecision and bias in the calculated multicomponent phi value itself.

Methods: Inter- and intra-assay phi precision was compared to precision of the individual component assays. QC measurements from total prostate-specific antigen (PSA), free PSA, and p2PSA were used to calculate a single calculated phi QC metric (PHIc). The frequency of QC failure of PHIc, relative to individual components QC by Westgard rules (13S and 22S), was determined. The effects of varying analyte component assay bias on the resulting PHIc metric were also examined.

Results: Average measured phi imprecision (6.7% CV) was higher than individual phi analyte component imprecision (3.9-4.5% CV) across 2 Beckman Coulter Unicel DxI 800 instruments. A retrospective examination of PHIc QC over 84 quality control determinations was concurrently carried out for both PHIc and component assay failure patterns, which were dependent on SDs utilized for Westgard evaluation. Finally, reinforcing nonlinear changes in PHIc were observed in select cases of introduced simulated bias of individual component measurements.

Conclusions: An additional calculated phi QC measure can be introduced to monitor MAAA precision/bias, and in principle calculated index controls may represent a complementary supplemental QC method that could be applied to other MAAA indices.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
用于 phi 多分析化验的计算指数控制方法的性能特征与算法分析。
背景:前列腺健康指数(phi)等算法分析法(MAAAs)越来越多地被用于生成疾病风险评分。目前,phi 的不精确性和偏差并不直接由指数的质量控制(QC)评估来监控,而是由单个成分的质量控制评估来监控。这可能无法充分控制计算出的多成分 phi 值本身的不精确性和偏差:方法:将测定间和测定内 phi 精确度与单个成分测定的精确度进行比较。总前列腺特异性抗原 (PSA)、游离 PSA 和 p2PSA 的 QC 测量值用于计算单一的 phi QC 指标 (PHIc)。根据韦斯特加德规则(13S 和 22S)确定了 PHIc QC 失败的频率。此外,还研究了不同分析成分检测偏差对 PHIc 指标的影响:结果:在两台贝克曼库尔特 Unicel DxI 800 仪器上,平均测量 phi 不精确度(6.7% CV)高于单个 phi 分析物组分不精确度(3.9-4.5% CV)。同时对84次质控测定的PHIc质控进行了回顾性检查,以了解PHIc和成分测定的失败模式,这取决于Westgard评估所使用的SD。最后,在单个成分测量引入模拟偏差的特定情况下,观察到 PHIc 的强化非线性变化:结论:可以采用额外的计算 phi 质量控制措施来监测 MAAA 的精度/偏差,原则上,计算的指数控制可以作为补充质量控制方法,应用于其他 MAAA 指数。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Applied Laboratory Medicine
Journal of Applied Laboratory Medicine MEDICAL LABORATORY TECHNOLOGY-
CiteScore
3.70
自引率
5.00%
发文量
137
期刊最新文献
Performance Characteristics of a Calculated Index Control Method for the phi Multianalyte Assay with Algorithmic Analysis. Unraveling Uncertainty: The Impact of Biological and Analytical Variation on the Prediction Uncertainty of Categorical Prediction Models. Fundamental Uncertainty: Interplatform Inconsistency of FDA-Cleared Serological Tests. Commentary on Myocarditis or Myositis? Rising, Declining, and Rising of Critical Cardiac Troponin T Levels in a Patient Post Immune Checkpoint Inhibitor Therapy. Myocarditis or Myositis? Rising, Declining, and Rising of Critical Cardiac Troponin T Levels in a Patient Post Immune Checkpoint Inhibitor Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1